Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of FHTX is 12 and suggests 127% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell